What You Should Know
- The FDA approved Rybrevant Faspro for certain adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum chemotherapy and immunotherapy.
- In a study of 102 patients, 42% had tumors that shrank or disappeared. Among those who responded, 56% maintained that response for at least six months.
- This was an accelerated approval. The treatment has not yet been proven to help patients live longer, and it is not indicated for HPV-associated cancer arising in the oropharynx.
This is the first new drug approved by the FDA in 10 years specifically for patients with recurrent or metastatic head and neck squamous cell carcinoma who previously received platinum chemotherapy. Still, the approval does not apply to everyone with head and neck cancer. Squamous cell carcinoma, the most common type of head and neck cancer, starts in the thin, flat cells lining the mouth, throat and voice box.b
Read MoreWho May Be Eligible?
Rybrevant Faspro is approved for adults with head and neck squamous cell carcinoma that is:- Either recurrent (the cancer returned after treatment) or metastatic (it spread to another part of the body)
- Growing after or during treatment with platinum chemotherapy
- Growing after or during treatment with an anti-PD-1 or PD-L1 immunotherapy
The chemotherapy and immunotherapy may have been given together or at different times.
The study did not include people who had already received a drug that targets EGFR (epidermal growth factor receptor, a protein that helps cancer cells grow), such as cetuximab (Erbitux), so less is known about how well Rybrevant Faspro works for them.
“Squamous cell carcinoma” describes a cancer that begins in the thin, flat cells lining areas such as the mouth, throat, and voice box.
What Is Rybrevant Faspro?
Rybrevant Faspro combines two medicines: amivantamab and hyaluronidase.
Amivantamab is a bispecific antibody. “Bispecific” means it can attach to two different targets: EGFR and MET (another protein that helps cancer cells grow and spread). Blocking those signals may slow cancer growth and help immune cells recognize and destroy the tumor.
Hyaluronidase helps the medication spread and become absorbed after it is injected under the skin. The injection is given in the abdomen over about five minutes. After three initial weekly doses, treatment is generally given every three weeks.
What Did the Study Show?
The FDA based the approval on OrigAMI-4, a clinical trial involving 102 patients. Everyone received Rybrevant Faspro; there was no separate group receiving another treatment.
The overall response rate was 42%. This means that 42% of patients had tumors that became smaller or disappeared on scans:
- 15% had a complete response, meaning no cancer could be seen on the scans used to measure response.
- 28% had a partial response, meaning the tumors became smaller but did not disappear completely.
The percentages do not total exactly 42% because of rounding.
“The response rate of 42% is encouraging, particularly given that these patients have already received chemotherapy and immunotherapy. This suggests that targeting multiple tumor-associated pathways may provide meaningful activity even after patients have exhausted standard treatment options,” Dr. Li said.
Among the patients whose cancer responded, 56% maintained that response for at least six months.
These results offer hope, particularly because currently available treatments in this setting have generally produced response rates of about 20% or lower. However, Rybrevant Faspro was not compared directly with another drug in this study.
What Does ‘Accelerated Approval’ Mean?
Accelerated approval allows the FDA to make a treatment available sooner when patients have a serious illness and limited options. It can be based on an early result, such as tumor shrinkage, that is considered likely to predict meaningful benefit.
In this case, the approval was based on how many tumors responded and how long those responses lasted. Researchers do not yet know whether Rybrevant Faspro helps patients live longer or delays cancer growth longer than other treatments.
A randomized study, in which patients are assigned by chance to different treatments, called OrigAMI-5, is required to confirm the benefit. The FDA may change or withdraw the indication (withdraw approval for this use) if that study does not verify a meaningful clinical benefit.
What Are the Side Effects?
The most common side effects include:
- Skin rash
- Tiredness
- Nail changes
- Mouth sores or inflammation
- Swelling caused by fluid buildup
Looking ahead, Dr. Li believes more notable developments are on the horizon for head and neck cancer patients.
“First, there are several other bispecific antibodies and ADCs (antibody-drug conjugates) in development with promising results in this space. Second, we need better biomarkers to identify which patients are most likely to benefit from specific treatments. Third, I expect continued development of therapies directed against novel molecular targets and tumor-specific mechanisms,” Dr. Li explains.
“Ultimately, our goal is to move beyond simply extending survival and toward achieving more durable disease control, preserving function, and improving quality of life for patients with head and neck cancer,” Dr. Li adds.
Questions to Ask Your Doctor
- Is my cancer the type covered by this approval?
- Was my oropharyngeal tumor tested for HPV or p16?
- Have I already received both platinum chemotherapy and immunotherapy?
- What does the 42% response rate mean for my situation?
- How will you try to prevent or manage skin and nail problems?
- What symptoms should lead me to call the office immediately?
- What other approved treatments or clinical trials could I consider?
Learn more about SurvivorNet's rigorous medical review process.

